Molecular Biomarkers for Gastric Cancer Targeted Therapies
DescriptionGastric cancer is the fourth most commonly diagnosed cancer and the third leading cause of cancer death. Even with more advanced surgical procedures and chemotherapy agents, the prognosis of patients with gastric cancer remains grim. While targeted- and irnmuno-therapies are revolutionizing treatments of many cancers, they have been less developed for gastric cancer. The paucity of identified oncogenic drivers, in particular gene fusions, in gastric adenocarcinoma makes focused gene fusion analysis of this tumor an urgent priority. We hypothesize that there remains actionable gene fusions to be uncovered in gastric adenocarcinoma, particularly in the genomically stable subtype. We aim to uncover novel gene fusions involving candidate genes, and investigate whether gene fusion is enriched among the Genomically Stable subtype of the TCGA molecular classification of gastric adenocarcinoma. Findings from this project would likely identify novel gene fusions and thus expand therapeutics options for targeted therapy in gastric cancer.
|Effective start/end date||1/04/16 → …|